Protara Therapeutics Inc (OQ:TARA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 345 Park Avenue South, 3Rd Floor
NEW YORK NY 10010
Tel: 1-646-8172836
Website: https://protaratx.com
IR: See website
<
Key People
Jesse Shefferman
President, Chief Executive Officer, Director 		Patrick Fabbio
Chief Financial Officer 		Jacqueline Zummo
Chief Scientific Operations Officer
Hannah Fry
Controller 		   
Business Overview
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Financial Overview
For the fiscal year ended 31 December 2023, Protara Therapeutics Inc revenues was not reported. Net loss decreased 39% to $40.4M. Lower net loss reflects Interest and investment income - Balanci increase from $1.1M (expense) to $454K (income), General and administrative - other decrease of 9% to $14M (expense), Stock-based Compensation in SGA decrease of 14% to $4.4M (expense).
Employees: 26 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$43.27M as of Dec 31, 2023
Net annual income (TTM): -$40.42M as of Dec 31, 2023
Free cash flow (TTM): -$37.60M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 11,433,837 as of Mar 8, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More